FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Neurologic Treatment in 20 Years

Executive Brief

News Report

The News: FDA approves tividenofusp alfa for treating neurologic manifestations of Hunter syndrome.
Clinical Win: This approval provides a new treatment option for pediatric patients with this rare disorder.
Target Specialty: pediatrics, neurology, rare disease specialists

Key Data at a Glance

Approval Date: March 25, 2026
Patient Population: Pediatric patients with Hunter syndrome
Average CSF HS Reduction: 91% at Week 24
Administration: IV infusion once weekly

The FDA approved tividenofusp alfa (Avlayah) on March 25, 2026, as the first treatment for neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients. This approval marks a significant advancement in the management of this rare genetic disorder, which primarily affects young boys and can lead to severe cognitive and physical impairments.

Clinical Context

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is an X-linked recessive disorder caused by a deficiency of the iduronate 2-sulfatase enzyme. This enzyme is crucial for breaking down glycosaminoglycans (GAGs), leading to their accumulation in various tissues, including the brain. The resultant buildup can cause progressive damage to organs, cognitive decline, and behavioral issues, often resulting in significant morbidity and mortality. Historically, treatment options for Hunter syndrome have been limited, with the last FDA-approved therapy being nearly two decades ago. The introduction of tividenofusp alfa represents a potential paradigm shift in care, specifically targeting the neurologic aspects of the disease.

Key Findings

The FDA approved the use of tividenofusp alfa (Avlayah) for treating neurologic manifestations of Hunter syndrome in pediatric patients weighing at least 5 kg when the treatment is initiated in presymptomatic or symptomatic stages prior to advanced neurologic impairment [1].

The approval was based on data from a phase 1/2 trial that enrolled 47 pediatric patients aged 3 months to 13 years, demonstrating a significant reduction in cerebrospinal fluid heparan sulfate (CSF HS) levels [1].

At Week 24, the average decrease in CSF HS was 91%, with a range of 72% to 98% reduction from baseline; 93% of patients achieved CSF HS levels below the upper limit of normal [1].

Avlayah is administered as an intravenous infusion once weekly and is the first therapy designed to penetrate the blood-brain barrier, addressing a critical unmet need in this patient population [1].

What This Means for Clinical Practice

The approval of tividenofusp alfa provides clinicians with a new tool to manage Hunter syndrome, particularly for neurologic symptoms that have historically been challenging to treat. This therapy is indicated for young patients, emphasizing the importance of early intervention to potentially alter the disease's trajectory. Clinicians should be aware of the boxed warning for allergic reactions, including anaphylaxis, associated with the drug. Ongoing clinical trials will further elucidate the long-term benefits and safety profile of tividenofusp alfa, which may influence future treatment guidelines and patient management strategies. As this is the first new treatment for Hunter syndrome in nearly 20 years, it offers hope for families affected by this debilitating condition, underscoring the necessity for early diagnosis and treatment initiation.

The FDA’s decision to grant accelerated approval based on biomarker data reflects a growing trend towards using surrogate endpoints in the approval process for rare diseases. This approach could pave the way for more rapid access to innovative therapies in the future, particularly for conditions with significant unmet medical needs. Clinicians should remain vigilant in monitoring patients for potential adverse effects and engage in shared decision-making with families regarding treatment options.

Clinical Perspective

Workflow: Clinicians will need to identify eligible pediatric patients early to initiate treatment with tividenofusp alfa.

Economics: The introduction of this therapy may impact healthcare costs associated with long-term care for Hunter syndrome.

Patient Outcomes: Early treatment with tividenofusp alfa may improve long-term cognitive and physical outcomes for affected children.

Editorial Team, Rare Disease

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Neurologic Treatment in 20 Years

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Rare Disease in your inbox.

Related Drug Updates

FDA Approves Marnetegragene Autotemcel for Severe LAD-I in Pediatrics

FDA Approves Tividenofusp Alfa for Hunter Syndrome: First Enzyme Replacement Therapy for Neurologic Symptoms

FDA Approves Doxecitine and Doxribtimine for Thymidine Kinase 2 Deficiency: Over 90% Survival Benefit

Verified HCP Portal